Chondrex, Inc.

Lipopolysaccharide from E. Coli 0111:B4

Catalog # 9028

For Research Use Only - Not Human or Therapeutic Use

DESCRIPTION: Lipopolysaccharide (LPS) from E. Coli 0111:B4 in PBS

APPLICATION: LPS has two independent unique activities: one is triggering inflammatory reactions and the other is stimulating B-cells to produce antibodies. Use these unique activities for triggering, synchronizing, or enhancing the development of arthritis in both collagen-induced arthritis (CIA) and collagen antibody-induced arthritis (CAIA) models.

A) In CAIA model: Use LPS to trigger arthritis in mice under the presence of sub-arthritogenic levels of autoantibodies to type II collagen.

1) Inject sub-arthritogenic dose of polyclonal antibodies or a cocktail of monoclonal antibodies into mice on day 0, and then inject 25-50 μg of LPS by IP to trigger the development of arthritis.

2) An additional IP injection of LPS on day 7-14 re-activates arthritis.

B) In CIA model: Use to stimulate autoantibody production and development of arthritis in mice immunized with type II collagen.

1) To synchronize arthritis development: Immunize mice with type II collagen/CFA on day 0 and then inject of 25-50 μg of LPS by IP on day 25-28, just before the expected onset of arthritis.

2) To stimulate antibody production and development of arthritis: Immunize mice with type II collagen/CFA on day 0 and then inject 20-50 μg of LPS by IP on day 21 or 28 to increase antibody production and the following development of arthritis.

3) To reactivate arthritis: Inject 25-50 μg of LPS by IP in mice on day 50-80, the late stage of CIA.

C) LPS is also used at low levels (0.01-1 μg/ml) as a positive control in vitro for stimulating the production and release of cytokines and chemokines.

QUANTITY: 5 ml

FORM: 0.5 mg/ml solution

SOURCE: E. coli 0111:B4

STORAGE TEMPERATURE: -20°C

STABILITY: 1 year

2607 151st Place NE
Redmond, WA 98052, USA
Phone: (425) 702-6365 or (888) 246-6373
Fax: (425) 882-3094
www.chondrex.com
info@chondrex.com